Neurocrine Biosciences, Inc. (NBIX) Posts Q1 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Neurocrine Bio. (NBIX) PT Trimmed at Jeffereis, 'Buy' Maintained
May 1, 2014 8:03 AM EDTJefferies analyst Thomas Wei trimmed his price target on Neurocrine Bio. (NASDAQ: NBIX) to $21.00 (from $23.00) but maintained a Buy rating following the company's Q1 update.
Wei comments, "On its 1Q14 call, NBIX focused on its upcoming FDA meeting and subsequent initiation... More
